GeneDx Holdings (WGS) Asset Writedowns and Impairment (2021 - 2026)

GeneDx Holdings (WGS) has reported Asset Writedowns and Impairment for 6 consecutive years, with $31.3 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $31.3 million in Q1 2026; TTM through Jun 2026 was $31.4 million, a 72974.42% increase from a year earlier, with the FY2025 full-year figure at $135000.0, down 25.0% from the prior year.
• Asset Writedowns and Impairment was $31.3 million for Q1 2026 at GeneDx Holdings, up from -$17000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $174.5 million in Q4 2022 and troughed at -$17000.0 in Q4 2025.
• A 5-year average of $24.0 million and a median of $152000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 17228.7% in 2022 and tumbled 139.53% in 2025, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $174.5 million in 2022, then plunged by 95.25% to $8.3 million in 2023, then sank by 99.48% to $43000.0 in 2024, then plunged by 139.53% to -$17000.0 in 2025, then jumped by 184141.18% to $31.3 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $31.3 million (Q1 2026), -$17000.0 (Q4 2025), and $152000.0 (Q3 2025), per Business Quant data.